Enanta Pharmaceuticals is a clinical stage biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (C0VID-19) and hepatitis B Virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).

Learn More »


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent Press Releases

November 22, 2023
Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference
November 20, 2023
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET

Upcoming Events

More events are coming soon.